✦ LIBER ✦

Update on active specific immunotherapy with melanoma vaccines

✍ Scribed by Conforti, Arnold M.; Ollila, David W.; Kelley, Mark C.; Gammon, Guy; Morton, Donald L.

Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 113 KB
Volume: 66
Category: Article
ISSN: 0022-4790
DOI: 10.1002/(sici)1096-9098(199709)66:1<55::aid-jso12>3.0.co;2-n

No coin nor oath required. For personal study only.

✦ Synopsis

Although a randomized clinical trial has yet to show a statistically significant improvement in the survival of patients receiving vaccine therapy for malignant melanoma, several studies have shown enhanced survival of patients developing an immune response to a melanoma vaccine. The knowledge and techniques of modern molecular biology and immunology suggest multiple strategies to augment this response. The challenge of immunotherapy research is to determine which combination of approaches leads to a favorable clinical response and how to monitor that response effectively. This review identifies components of a successful vaccine, discusses new ways to modulate and stimulate the immune system, and summarizes some of the more interesting clinical trials of melanoma vaccine immunotherapy.

📜 SIMILAR VOLUMES

Overview of melanoma vaccines: Active sp

Overview of melanoma vaccines: Active specific immunotherapy for melanoma patients

✍ David W. Ollila; Mark C. Kelley; Guy Gammon; Donald L. Morton 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

Although a phase III trial has yet to show a statistically significant improvement in the disease-free or overall survival of melanoma patients receiving vaccine therapy, several phase II trials have shown enhanced disease-free and overall survival of patients who develop a humoral and/or cellular r

Active specific immunotherapy with polyv

Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases

✍ Eddy C. Hsueh; Larry Nathanson; Leland J. Foshag; Richard Essner; J. Anne Nizze; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 341 KB 👁 1 views

## BACKGROUND. This study was conducted to document the rate, duration, and type of objective response to active specific immunotherapy with a polyvalent melanoma cell vaccine (PMCV) for patients with in-transit melanoma metastases and to identify any acute or chronic toxic effects of PMCV treatme

In vivo activation of melanoma-specific

In vivo activation of melanoma-specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells

✍ Daniel E. Speiser; Danielle Liénard; Mikaël J. Pittet; Pascal Batard; Donata Rim 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 210 KB 👁 1 views

Synthesis of QS-21-Xylose: Establishment

Synthesis of QS-21-Xylose: Establishment of the Immunopotentiating Activity of Synthetic QS-21 Adjuvant with a Melanoma Vaccine

✍ Kai Deng; Michelle M. Adams; Payal Damani; Philip O. Livingston; Govind Ragupath 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 401 KB

Synthesis of QS-21-Xylose: Establishment

Synthesis of QS-21-Xylose: Establishment of the Immunopotentiating Activity of Synthetic QS-21 Adjuvant with a Melanoma Vaccine

✍ Kai Deng; Michelle M. Adams; Payal Damani; Philip O. Livingston; Govind Ragupath 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 401 KB

Epitope-specific immunotherapy of rheuma

Epitope-specific immunotherapy of rheumatoid arthritis: Clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial

✍ Eva C. Koffeman; Mark Genovese; Diane Amox; Elissa Keogh; Ernesto Santana; Eric 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB